| Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure (NCT02080767) | U.S. Army Medical Research and Development Command | |
| Early Access Program for Zolbetuximab (NCT06048081) | Astellas Pharma Global Development, Inc. | |
| Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors (NCT06872489) | Second Life Therapeutics | |
| Eculizumab (Soliris) in Covid-19 Infected Patients (NCT04288713) | Hudson Medical | |
| Expanded Access for d-MAPPS™ Ophthalmic Solution, in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD) (NCT07210619) | Regenerative Ocular Immunobiologics LLC | |
| Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009 (NCT05134922) | Celcuity Inc | |
| Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer (NCT01786850) | University of Roma La Sapienza | |
| A Multicenter Randomized Parallel-group Study to Investigate the Efficacy of a Combination of Rosuvastatin and Fenofibrate in the Patients With Diabetes or Atherosclerotic Vascular Diseases With Metabolic Syndrome (NCT00965315) | National Taiwan University Hospital | |
| Expanded Access:18F-Fluorocholine for the Detection of Parathyroid Adenomas (NCT07218224) | Thomas Hope | |
| An Expanded Access Program for SYN023 in Rabies Treatment (NCT07706907) | Synermore Biologics (Suzhou) Co., Ltd. | |
| Molgramostim Nebulizer Solution Expanded Access Program Protocol (NCT06546098) | Savara Inc. | |
| A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp (NCT04960891) | Immunocore Ltd | |
| Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease (NCT05572996) | Ferrer Internacional S.A. | |
| Expanded Access [11C] Methionine PET Imaging (NCT05511714) | St. Jude Children's Research Hospital | |
| Accuracy and Reliability of GSA for Remnant Liver Function (NCT02013895) | Kochi University | |
| Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial) (NCT05612191) | Advenchen Laboratories, LLC | |
| Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients. (NCT06025227) | Pfizer | |
| TB006 Expanded Access (EA) Compassionate Use (NCT05959239) | TrueBinding, Inc. | |
| Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease (NCT03865836) | Amicus Therapeutics | |
| Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer (NCT02209441) | Chinese Academy of Medical Sciences | |
| Olpasiran Expanded Access Program (NCT07079267) | Amgen | |
| Osteopathic Approach Into Neonatology Ward: the NE-O Model (NCT01902563) | European Institute for Evidence Based Osteopathic Medicine | |
| Cannabidiol for Drug Resistant Pediatric Epilepsy (Expanded Access Use) (NCT03676049) | John | |
| To Validate the Specific Patterns of Magnetocardiography, a Non-invasive Non-contact Examination for Patients With Ischemic Heart Disease or Cardiac Arrhythmia (NCT00965614) | National Taiwan University Hospital | |
| ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer (NCT06810141) | ImmunityBio, Inc. | |
| Pre-approval Expanded Access of Retatrutide (LY3437943) (NCT07629401) | Eli Lilly and Company | |
| Managed Access Programs for AIN457, Secukinumab (NCT05583604) | Novartis Pharmaceuticals | |
| TETRAVI Expanded Access Program (NCT07104591) | Baylor College of Medicine | |
| An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) (NCT06939647) | Insmed Incorporated | |
| Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colitis or Crohn's Disease in the USA (NCT06856135) | Takeda | |
| Expanded Access to Velmanase Alfa (NCT04959240) | Chiesi Farmaceutici S.p.A. | |
| Zilganersen Expanded Access Program for Individuals With Alexander Disease (NCT07487389) | Ionis Pharmaceuticals, Inc. | |
| Expanded Access to Mepsevii (NCT03775174) | Ultragenyx Pharmaceutical Inc | |
| AMG 335 Expanded Access Program for IgG4-Related Disease (NCT06590051) | Amgen | |
| Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation (NCT06761976) | Bayer | |
| Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors (NCT06963697) | Jaime Leandro Foundation for Therapeutic Cancer Vaccines | |
| Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling (NCT04710056) | Regeneron Pharmaceuticals | |
| Expanded Access to TAK-881 for People With Primary Immunodeficiency Diseases in the USA and Czech Republic (NCT06955793) | Takeda | |
| Expanded Access to Upadacitinib (NCT04159597) | AbbVie | |
| Expanded Access for Inhaled Isoflurane Delivered Via the Sedaconda ACD-S for Sedation of Difficult-to-Sedate Adult Mechanically Ventilated Intensive Care Unit Patients (NCT07457593) | Sedana Medical | |
| Expanded Access to Zofin for Patients With COVID-19 (NCT04657406) | ZEO ScientifiX, Inc. | |